Neurolief Secures Major Funding for At-Home Depression Therapy
March 31, 2026, 4:00 pm
Neurolief secures $6M from BrainsWay. FDA approved its ProlivRx system. This brain neuromodulation therapy treats major depressive disorder at home. It targets patients resistant to antidepressants. The investment fuels U.S. rollout. It vastly expands access to advanced mental healthcare.
Coral Springs, FL – Neurolief, a pioneering medical technology firm, recently closed a significant funding round. The company secured a $6 million investment. BrainsWay Ltd. provided this capital infusion. This investment follows a major regulatory achievement. The U.S. Food and Drug Administration (FDA) granted Premarket Approval (PMA) for Neurolief’s ProlivRx system. This green light marks a pivotal moment for mental health treatment.
ProlivRx represents a new frontier. It is a prescription brain neuromodulation system. It targets adults with major depressive disorder (MDD). These are patients who have not found sufficient relief from standard antidepressant medications. The therapy offers a crucial alternative. It addresses a persistent treatment gap.
The system’s key innovation lies in its delivery model. ProlivRx is self-administered. Patients use it at home. A physician supervises the treatment remotely. This model removes traditional access barriers. It brings advanced care directly to the patient. No longer do individuals need specialized treatment facilities.
Major depressive disorder impacts millions. Many suffer despite trying multiple medications. These patients often face difficult choices. Traditional next-step therapies exist. They include transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT). These require in-clinic visits. Logistical challenges arise. Travel, scheduling, and facility availability are common hurdles. ProlivRx bypasses these issues.
The $6 million investment will fuel expansion. Neurolief plans to scale its operations. Research and development efforts will also accelerate. The company aims to broaden commercial adoption of ProlivRx. This means reaching more patients. It means making the therapy a standard option.
FDA Premarket Approval is a rigorous process. It validates ProlivRx’s safety and efficacy. The approval confirms its clinical benefits. This regulatory milestone provides strong market credibility. It opens doors for widespread adoption. Doctors can now prescribe ProlivRx with confidence.
BrainsWay’s investment signifies strategic alignment. BrainsWay is a known leader in neurostimulation. They specialize in Deep Transcranial Magnetic Stimulation (Deep TMS). Their platform holds multiple FDA clearances. These span various mental health and addiction disorders. This partnership underscores increasing industry momentum. Non-invasive neurostimulation technologies gain wider acceptance.
The collaboration brings together expertise. Neurolief’s innovation meets BrainsWay’s market experience. This strengthens ProlivRx’s U.S. rollout. It enhances the therapy’s reach. It builds a robust delivery model.
The healthcare landscape is evolving. Value-based care models are gaining traction. These models prioritize patient outcomes and cost-effectiveness. ProlivRx fits this paradigm perfectly. It offers an effective, accessible solution. It reduces reliance on expensive, facility-based treatments. It supports earlier intervention.
Clinicians face pressures. They must reach high-need depression patients efficiently. ProlivRx empowers them. It expands their capacity for care. It helps them overcome infrastructure constraints. This leads to better patient management. It ensures more people receive timely treatment.
Neurolief's vision is clear. They aim to integrate clinically validated neuromodulation into everyday care. ProlivRx serves as a cornerstone for this mission. It offers a tangible solution. It transforms how chronic depression is managed. The focus is on patient convenience and effectiveness.
The demand for scalable mental health solutions is immense. Global mental health crises are escalating. Innovative approaches are critical. ProlivRx offers one such solution. It represents a shift. Care moves from specialized centers to the comfort of home. This enhances patient autonomy. It also reduces stigma associated with facility visits.
Research and development remain central for Neurolief. The company continually seeks advancements. They aim to improve existing therapies. They explore new applications for neuromodulation. This commitment ensures sustained innovation. It promises future benefits for patients.
The investment from BrainsWay is milestone-based. This structure incentivizes performance. It ensures strong alignment between the partners. It reflects confidence in Neurolief’s execution capabilities. It validates ProlivRx’s market potential.
Mental health innovation is crucial. Non-invasive brain stimulation offers hope. It provides new avenues for treatment. ProlivRx stands at the forefront of this movement. It offers a powerful tool. It helps patients regain control over their lives. It represents progress in a vital healthcare sector.
This funding round positions Neurolief for significant growth. The company is set to disrupt depression care. It will expand access to advanced therapies. ProlivRx will empower patients. It will support clinicians. It will change the conversation around mental health treatment access. The future of depression therapy looks more accessible. It looks brighter.
Coral Springs, FL – Neurolief, a pioneering medical technology firm, recently closed a significant funding round. The company secured a $6 million investment. BrainsWay Ltd. provided this capital infusion. This investment follows a major regulatory achievement. The U.S. Food and Drug Administration (FDA) granted Premarket Approval (PMA) for Neurolief’s ProlivRx system. This green light marks a pivotal moment for mental health treatment.
ProlivRx represents a new frontier. It is a prescription brain neuromodulation system. It targets adults with major depressive disorder (MDD). These are patients who have not found sufficient relief from standard antidepressant medications. The therapy offers a crucial alternative. It addresses a persistent treatment gap.
The system’s key innovation lies in its delivery model. ProlivRx is self-administered. Patients use it at home. A physician supervises the treatment remotely. This model removes traditional access barriers. It brings advanced care directly to the patient. No longer do individuals need specialized treatment facilities.
Major depressive disorder impacts millions. Many suffer despite trying multiple medications. These patients often face difficult choices. Traditional next-step therapies exist. They include transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT). These require in-clinic visits. Logistical challenges arise. Travel, scheduling, and facility availability are common hurdles. ProlivRx bypasses these issues.
The $6 million investment will fuel expansion. Neurolief plans to scale its operations. Research and development efforts will also accelerate. The company aims to broaden commercial adoption of ProlivRx. This means reaching more patients. It means making the therapy a standard option.
FDA Premarket Approval is a rigorous process. It validates ProlivRx’s safety and efficacy. The approval confirms its clinical benefits. This regulatory milestone provides strong market credibility. It opens doors for widespread adoption. Doctors can now prescribe ProlivRx with confidence.
BrainsWay’s investment signifies strategic alignment. BrainsWay is a known leader in neurostimulation. They specialize in Deep Transcranial Magnetic Stimulation (Deep TMS). Their platform holds multiple FDA clearances. These span various mental health and addiction disorders. This partnership underscores increasing industry momentum. Non-invasive neurostimulation technologies gain wider acceptance.
The collaboration brings together expertise. Neurolief’s innovation meets BrainsWay’s market experience. This strengthens ProlivRx’s U.S. rollout. It enhances the therapy’s reach. It builds a robust delivery model.
The healthcare landscape is evolving. Value-based care models are gaining traction. These models prioritize patient outcomes and cost-effectiveness. ProlivRx fits this paradigm perfectly. It offers an effective, accessible solution. It reduces reliance on expensive, facility-based treatments. It supports earlier intervention.
Clinicians face pressures. They must reach high-need depression patients efficiently. ProlivRx empowers them. It expands their capacity for care. It helps them overcome infrastructure constraints. This leads to better patient management. It ensures more people receive timely treatment.
Neurolief's vision is clear. They aim to integrate clinically validated neuromodulation into everyday care. ProlivRx serves as a cornerstone for this mission. It offers a tangible solution. It transforms how chronic depression is managed. The focus is on patient convenience and effectiveness.
The demand for scalable mental health solutions is immense. Global mental health crises are escalating. Innovative approaches are critical. ProlivRx offers one such solution. It represents a shift. Care moves from specialized centers to the comfort of home. This enhances patient autonomy. It also reduces stigma associated with facility visits.
Research and development remain central for Neurolief. The company continually seeks advancements. They aim to improve existing therapies. They explore new applications for neuromodulation. This commitment ensures sustained innovation. It promises future benefits for patients.
The investment from BrainsWay is milestone-based. This structure incentivizes performance. It ensures strong alignment between the partners. It reflects confidence in Neurolief’s execution capabilities. It validates ProlivRx’s market potential.
Mental health innovation is crucial. Non-invasive brain stimulation offers hope. It provides new avenues for treatment. ProlivRx stands at the forefront of this movement. It offers a powerful tool. It helps patients regain control over their lives. It represents progress in a vital healthcare sector.
This funding round positions Neurolief for significant growth. The company is set to disrupt depression care. It will expand access to advanced therapies. ProlivRx will empower patients. It will support clinicians. It will change the conversation around mental health treatment access. The future of depression therapy looks more accessible. It looks brighter.